Zonagen divests Fertility Technologies:
This article was originally published in Clinica
Zonagen, a reproductive health, sexual dysfunction and urologic pharmaceuticals company has sold its wholly-owned Fertility Technologies to SAGE BioPharma. The Woodlands, Texas-based Fertility Technologies markets and distributes a number of diagnostics and devices involved in so-called assisted reproductive technique procedures. The terms of the sale were not disclosed, although Zonagen said that the subsidiary was sold as it did not represent Zonagen's core business of drug discovery.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.